Theravance Biopharma, INC Form 4 insider transactions

Rhonda Farnum, SVP at Theravance Biopharma, reports disposing of 9,120 ordinary shares to cover tax obligations arising from vesting restricted stock units.

Aine Miller, SVP at Theravance Biopharma, reports acquisition of 10,430 shares via RSU vesting and disposition of 9,701 shares to cover tax obligations.

Director Deepika Pakianathan reports the acquisition of stock options and disposal of ordinary shares in Theravance Biopharma.

Director Donal O'Connor reports acquisition of shares and options in Theravance Biopharma, Inc.

Dean J. Mitchell, a director of Theravance Biopharma, acquired shares and options in a transaction dated May 19, 2025.

Director Susannah Gray reports acquisition of Theravance Biopharma shares and options, signaling potential confidence in the company's future.

Director Jeremy T. Grant reports acquisition of share options and disposal of ordinary shares in Theravance Biopharma, Inc.

Director Eran Broshy reports acquisition of shares and options in Theravance Biopharma.

Director Laurie Smaldone Alsup reports acquisition of Theravance Biopharma shares and options, signaling potential confidence in the company's future.

Rhonda Farnum, SVP, COMM & MEDICAL AFFAIRS at Theravance Biopharma, sold 4,000 ordinary shares at $9 per share on April 21, 2025, according to a Form 4 filing.

Rick E. Winningham, CEO of Theravance Biopharma, acquired 2,178 ordinary shares at $9.35 per share under the company's equity incentive plan.

Aziz Sawaf, CFO of Theravance Biopharma, reports acquiring 75,000 ordinary shares on February 28, 2025.

Aine Miller, SVP at Theravance Biopharma, reports acquiring 75,000 ordinary shares on February 28, 2025.

Brett A. Grimaud, SVP, General Counsel, and Secretary of Theravance Biopharma, Inc., acquired 75,000 ordinary shares on February 28, 2025.

Rhonda Farnum, SVP, COMM & MEDICAL AFFAIRS at Theravance Biopharma, acquired 75,000 ordinary shares on February 28, 2025.

Rick Winningham, CEO of Theravance Biopharma, reports the disposal of shares to cover tax obligations related to vesting restricted stock units.

Aziz Sawaf, CFO of Theravance Biopharma, disposed of shares to cover tax obligations related to vesting restricted stock units.

Aine Miller, SVP at Theravance Biopharma, disposed of 11,295 ordinary shares to cover tax obligations related to vesting restricted stock units.

Brett A. Grimaud, SVP, General Counsel, and Secretary of Theravance Biopharma, Inc., disposed of shares to cover tax obligations related to vesting restricted stock units.

Rhonda Farnum, SVP, COMM & MEDICAL AFFAIRS at Theravance Biopharma, reports the vesting of performance-based restricted stock units and shares withheld for tax obligations.

Rhonda Farnum, SVP at Theravance Biopharma, sold 4,000 ordinary shares at $9 each, as part of a pre-arranged 10b5-1 trading plan.

Theravance Biopharma's CEO, Rick E. Winningham, sold 15,997 shares to cover tax obligations related to vesting restricted stock units.

Aziz Sawaf, SVP & CFO of Theravance Biopharma, sold 8,477 ordinary shares to cover tax obligations related to vesting restricted stock units.

Theravance Biopharma's SVP, Aine Miller, sold 10,076 ordinary shares to cover tax obligations related to vesting restricted stock units.

A Theravance Biopharma executive, Brett A. Grimaud, sold 9,268 shares to cover tax obligations related to vesting restricted stock units.

A Theravance Biopharma executive, Rhonda Farnum, sold 9,178 shares to cover tax obligations related to vesting restricted stock units.

Theravance Biopharma's CEO, Rick E. Winningham, acquired 3,193 ordinary shares at $9.57 per share, in a transaction reported late due to an administrative error.

Rhonda Farnum, SVP at Theravance Biopharma, sold 4,000 ordinary shares at $9 each, according to a recent SEC filing.

CEO Rick Winningham of Theravance Biopharma reports disposal of shares to cover tax obligations related to vesting restricted stock units.

Aziz Sawaf, CFO of Theravance Biopharma, disposed of 8,635 ordinary shares to cover tax obligations related to vesting restricted stock units.